BiotechTube

Shenfu Zhusheye + 5% glucose injection

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Acute Heart Failure

Conditions

Acute Heart Failure

Trial Timeline

Sep 3, 2014 → Mar 24, 2017

NCT ID
NCT02135835

About Shenfu Zhusheye + 5% glucose injection

Shenfu Zhusheye + 5% glucose injection is a approved stage product being developed by China Resources Pharmaceutical Group for Acute Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT02135835. Target conditions include Acute Heart Failure.

What happened to similar drugs?

20 of 20 similar drugs in Acute Heart Failure were approved

Approved (20) Terminated (4) Active (0)
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
✅Sitafloxacin + Moxifloxacin HydrochlorideDaiichi SankyoApproved
✅micafungin + posaconazoleAstellas PharmaApproved
✅Selbex + SelbexEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02135835ApprovedCompleted

Competing Products

20 competing products in Acute Heart Failure

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 (Celecoxib Oral Solution) 62.5 mg + DFN-15 (Celecoxib Oral Solution) 125 mg + DFN-15 (Celecoxib Oral Solution) 250 mg + PlaceboDr. Reddy's LaboratoriesPhase 2
32
AFM28AffimedPhase 1
11
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
Oliceridine + Placebo + MorphineTrevenaPhase 3
30
TRV130TrevenaPhase 3
30
TRV130 + Morphine + PlaceboTrevenaPhase 2
25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
SPT-07A injectionSinopharmPhase 3
36
PRGN-3006 T CellsPrecigenPhase 1
27
BisantreneRace OncologyPhase 2
29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
15
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
25
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
ZN-d5Zentalis PharmaceuticalsPhase 1
19